May 27 | 2021
2cureX offentliggör delårsrapport för det första kvartalet 2021
Read more
May 27 | 2021
2cureX publishes interim report for the first quarter of 2021
Read more
May 27 | 2021
Kommuniké från årsstämma i 2cureX AB
Read more
May 27 | 2021
Communiqué from the Annual General Meeting of 2cureX AB
Read more
May 20 | 2021
2cureX’s clinical partner, University Hospital Vejle, presents positive results of the IndiTreat®-guided clinical trial in third line metastatic colorectal cancer at the ASCO 2021 Annual Meeting
Read more
May 11 | 2021
Warrants of series TO1 were subscribed to approximately 96.75 percent and 2cureX AB receives approximately SEK 31.40 million.
Read more
May 11 | 2021
Teckningsoptioner av serie TO1 tecknades till cirka 96,75 procent och 2cureX AB tillförs cirka 31,40 MSEK
Read more
May 6 | 2021
Mangold Fondkommission AB published an Analyst Report on 2cureX
Read more
May 6 | 2021
2cureX offentliggör årsredovisning för räkenskapsåret 2020
Read more
May 6 | 2021
2cureX publishes the annual report for the fiscal year 2020
Read more
May 5 | 2021
Sista dag för handel med teckningsoptionerna av serie TO1 i 2cureX AB är idag, den 5 maj 2021
Read more
April 27 | 2021
2cureX’s CEO Fernando Andreu is buying shares in the company
Read more
April 26 | 2021
2cureX styrelse och ledning nyttjar samtliga innehavda teckningsoptioner av serie TO1 för 6,04 MSEK
Read more
April 26 | 2021
Board and management of 2cureX exercise all held warrants of series TO1 for SEK 6.04 million
Read more
April 24 | 2021
Correction of “Notice to attend the Annual General Meeting of 2cureX AB” issued on 23[rd] April 2021.
Read more
April 24 | 2021
Korrektion till ”Kallelse till årsstämma i 2cureX AB” utfärdad den 23 april 2021.
Read more
April 23 | 2021
Notice to attend the Annual General Meeting of 2cureX AB
Read more
April 23 | 2021
Kallelse till årsstämma i 2cureX AB
Read more